Amedisys (AMED)
(Delayed Data from NSDQ)
$96.71 USD
-0.09 (-0.09%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $96.71 0.00 (0.00%) 7:04 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.71 USD
-0.09 (-0.09%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $96.71 0.00 (0.00%) 7:04 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Zacks News
Amedisys & BrightStar Ink Agreement to Expand Personal Care
by Zacks Equity Research
Amedisys (AMED) strengthens Personal Care business reach by entering into an agreement with BrightStar.
Amedisys Banks on Coronavirus-Driven Growth Amid Cost Woes
by Zacks Equity Research
Amedisys (AMED) has been benefiting from the recent acquisitions of hospice care providers.
Amedisys (AMED) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Amedisys' (AMED) second-quarter results reflect impressive performance by the Hospice division despite pandemic-led challenges.
Amedisys (AMED) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 69.62% and 4.30%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Amedisys (AMED) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amedisys Rides on Coronavirus-Led Business Amid Cost Woes
by Zacks Equity Research
Amedisys (AMED) while seeing a drop in MIS visits is experiencing steady recovery in referral volumes.
Why the Earnings Surprise Streak Could Continue for Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ADUS vs. AMED: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. AMED: Which Stock Is the Better Value Option?
Healthcare for Silver Years to Aid Encompass Health (EHC)
by Zacks Equity Research
Encompass Health's (EHC) inpatient rehabilitation and home hospice businesses are poised to grow on the back of aging population.
Amedisys Rides on Hospice Arm Expansion Amid Coronavirus Woes
by Zacks Equity Research
Amedisys (AMED) benefits from the recent acquisitions of hospice care providers, Asana Hospice, RoseRock Healthcare and Compassionate Care Hospice.
DGX vs. AMED: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. AMED: Which Stock Is the Better Value Option?
Here's Why You Should Add Ensign Group to Your Portfolio
by Zacks Equity Research
Strategic initiatives and a healthy balance sheet make Ensign Group (ENSG) an attractive pick for investors.
Amedisys (AMED) Up 2.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Broadens Hospice Base With AseraCare Buyout
by Zacks Equity Research
Amedisys (AMED) expects AseraCare business to add greater scale to its existing nationwide network.
Hospital Industry's Dull Near-Term Outllook Induced by Coronavirus
by Sapna Bagaria
Revenue loss and cost rise due to coronavirus outbreak put hospital companies in a tight spot.
The Zacks Analyst Blog Highlights: Brookdale Senior Living, The Ensign Group, Amedysis and Chemed
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Brookdale Senior Living, The Ensign Group, Amedysis and Chemed
Silver Tsunami to Hit the United States: 4 Stocks in Focus
by Aparajita Dutta
There are approximately 35 million Americans aged 65 or older currently and this number is expected to double in the next 25 years.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Amedisys (AMED) Q1 Earnings Beat, Operating Margin Falls
by Zacks Equity Research
Amedisys (AMED) notes that COVID-19 started impacting its volumes and costs beginning the second half of March.
Amedisys (AMED) Beats Q1 Earnings Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 8.25% and -4.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: Vertex Pharmaceuticals, Alibaba, Amedisys and Fabrinet
by Zacks Equity Research
Zacks.com featured highlights include: Vertex Pharmaceuticals, Alibaba, Amedisys and Fabrinet
Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio
by Sumit Singh
Interest Coverage Ratio suggests how many times the interest could be paid from earnings and gauges the margin of safety a firm has for paying interest.
Zacks.com featured highlights include: NEE, FNV, AMED, ATO and COST
by Zacks Equity Research
Zacks.com featured highlights include: NEE, FNV, AMED, ATO and COST
Bet on These 5 Low Leverage Stocks to Avoid Huge Losses
by Zacks Equity Research
With the earnings season in full swing, the real challenge for an investor is determining whether an organization's debt level is sustainable.